Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Long term survival data from the Phase III Keynote-054 trial

Matteo Carlino • 11 Sep 2022
ESMO 2022
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Pembrolizumab
KEYNOTE-054

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, provides an overview of 5-year follow-up results from the Phase III EORTC 1325-MG/Keynote-054 trial (NCT02362594) of pembrolizumab in high-risk stage III melanoma. The practice-changing trial demonstrates the long-term efficacy of pembrolizumab, with high rates of relapse-free survival observed in the patient cohort. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Matteo Carlino

KEYNOTE-942: 5 year update of intismeran and pembrolizumab in melanoma
0:47
KEYNOTE-942: 5 year update of intismeran and pembrolizumab in melanoma
Matteo Carlino • 1 Jun 2026
Checkpoint inhibitor retreatment after immune-related toxicity
1:01
Checkpoint inhibitor retreatment after immune-related toxicity
Matteo Carlino • 1 Jun 2026
DYP688 as a treatment option in patients with HLA-A*02:01-negative MUM
0:56
DYP688 as a treatment option in patients with HLA-A*02:01-negative MUM
Matteo Carlino • 1 Jun 2025
Evaluating DYP688 and the future of GNAQ/11-targeted therapy in melanoma
1:12
Evaluating DYP688 and the future of GNAQ/11-targeted therapy in melanoma
Matteo Carlino • 1 Jun 2025

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals